RemeGen (荣昌生物) IPO: Pricing the R&D Leadership
RemeGen is a China-based commercial-ready biopharmaceutical company with a focus on first-in-class and best-in-class biologics in the area of...
393 Views
RemeGen IPO Initiation: Seeking a Cure
RemeGen currently has a pipeline of more than ten drug candidates. Overall, we believe that the prospectus RemeGen’s core drug assets (telitacept,...
297 Views
Pre-IPO RemeGen - Insights on Two Core Products RC18 & RC48
This article analyzed two core products from RemeGen: RC18 and RC 48. The commercialization of these two products would have direct impact on the...
405 Views
RemeGen (荣昌生物) Pre-IPO: Thoughts on Valuation of RC18 and RC48
RemeGen is a China-based commercial-ready biopharmaceutical company with a focus on first-in-class and best-in-class biologics in the area of...
696 Views
RemeGen (荣昌生物) Pre-IPO: Top-Notch R&D Capability and a Strong Team
RemeGen is a China-based commercial-ready biopharmaceutical company with a focus on first-in-class and best-in-class biologics in the area of...
524 Views